Home / World / World Lifestyle / Archive by category Health & Medical (Page 27)

Archive by category Health & Medical

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

SHANGHAI, China, April 07, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for toripalimab (product code: JS001) [...]

NeuroVigil, World’s Most Valuable Neurotech, Launches iBrain™ in US

CLOSED 6 BILLION DOLLAR SERIES B DEAL SAN FRANCISCO, April 05, 2024 (Korea Bizwire) – Silicon Valley-based Neurotechnology Powerhouse, announced that it launched its non-invasive iBrain™ Personal Brain Monitor, in 4 US states on Friday and sold 1.4% of its stock for more than $85 million, valuing the company at over $6 Billion in the [...]

Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)

INCHEON, Korea, April 05, 2024 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company’s proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda [...]

NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

CLOSED 6 BILLION DOLLAR SERIES B DEAL SAN FRANCISCO, April 05, 2024 (Korea Bizwire) – In a release issued under the same headline on Thursday, April 4, 2024 by NeuroVigil, Inc., please note the contact information should be press@neurovigil.com. The corrected release follows: Silicon Valley-based Neurotechnology Powerhouse, announced that it launched its non-invasive iBrain™ Personal Brain Monitor, [...]

Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative Pressure Wound Therapy System (sNPWT). NICE have reviewed ‘Medical Technology Guideline 43 PICO negative pressure wound dressings for closed surgical incisions’ which recognises that [...]

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Strategic partnership expands Biognosys’ services to include Alamar’s NULISA assays as well as joint scientific research in biofluid-based proteomics Complementary value of Biognosys’ DIA-MS unbiased proteomics platform and Alamar’s game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (Korea Bizwire) – Biognosys, a global [...]

KFSH&RC Welcomes Dr. Björn Zoéga as New Deputy CEO

King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024. This strategic move is set to accelerate KFSH&RC’s aspiration of becoming a leading healthcare institution on the global stage, leveraging Dr. Zoéga’s notable career and proven track [...]

Information on the Total Number of Voting Rights and Shares (Nyxoah)

Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET (Korea Bizwire) – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new [...]

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, China, March 29, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 [...]

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

VANCOUVER, British Columbia, March 28, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. “Dr. Gallagher is the [...]